Dearborn Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Dearborn Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,283	Closed	-$204K	–	247
2022 Q4	$204K	Buy	+1,283	New	+$188K	0.01%	238
2022 Q3	–	Sell	-1,353	Closed	-$211K	–	261
2022 Q2	$211K	Hold	1,353	–	–	0.01%	245
2022 Q1	$211K	Buy	+1,353	New	+$196K	0.01%	265
2021 Q3	–	Sell	-1,353	Closed	-$240K	–	256
2021 Q2	$240K	Hold	1,353	–	–	0.01%	226
2021 Q1	$222K	Sell	1,353 -800	-37%	-$132K	0.01%	230
2020 Q4	$355K	Hold	2,153	–	–	0.02%	182
2020 Q3	$307K	Hold	2,153	–	–	0.02%	185
2020 Q2	$238K	Hold	2,153	–	–	0.01%	195
2020 Q1	$215K	Buy	2,153 +400	+23%	+$51.7K	0.01%	201
2019 Q4	$262K	Hold	1,753	–	–	0.01%	211
2019 Q3	$225K	Hold	1,753	–	–	0.01%	217
2019 Q2	$250K	Hold	1,753	–	–	0.02%	182
2019 Q1	$251K	Hold	1,753	–	–	0.02%	176
2018 Q4	$217K	Hold	1,753	–	–	0.02%	191
2018 Q3	$295K	Hold	1,753	–	–	0.02%	155
2018 Q2	$302K	Hold	1,753	–	–	0.02%	136
2018 Q1	$265K	Hold	1,753	–	–	0.02%	146
2017 Q4	$236K	Hold	1,753	–	–	0.02%	162
2017 Q3	$256K	Hold	1,753	–	–	0.02%	150
2017 Q2	$273K	Hold	1,753	–	–	0.02%	141
2017 Q1	$254K	Buy	+1,753	New	+$228K	0.02%	147

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Dearborn Partners's JAZZ Position: Q1 2023 in Review

Dearborn Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 1,283 shares — an estimated $204K sold.

Dearborn Partners first reported a position in JAZZ in Q1 2017 and held it in 21 quarters. The position peaked at $355K in Q4 2020. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Dearborn Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Dearborn Partners sold 1,283 Jazz Pharmaceuticals shares in Q1 2023, an estimated $204K.
Dearborn Partners first reported a position in Jazz Pharmaceuticals in Q1 2017 and held it in 21 quarters.
Dearborn Partners's Jazz Pharmaceuticals position peaked at $355K in Q4 2020.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Dearborn Partners's 13F filing for Q1 2023, filed 4 May 2023.